Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

CAR T Therapies Could Transform Neuro-Immune Disease Treatment

Chimeric antigen receptor T (CAR T) cell therapies are rapidly gaining attention among neurologists as groundbreaking treatments for neuro-immune diseases. Recent findings indicate that 77% of neurologists surveyed see CAR T therapies as potential game-changers that could displace existing standards of care. As healthcare …

Vinay Lochav | 25 August 2026

Medicare Advantage Fails to Improve Diabetes Care Against Traditional Medicare

Medicare Advantage is under scrutiny as a new study indicates that enrollees with diabetes do not have better health results than those in traditional Medicare. This revelation calls into question the efficacy of Medicare Advantage's additional features, such as gym memberships and grocery benefits, …

Vinay Lochav | 25 August 2026

Pfizer (NYSE: PFE) Q2 Revenue Grows 1% to $15B, Eyes Patent Expirations

The uptick reflects a noticeable shift, as growth sources diversify away from pandemic-related products, which had previously dominated sales. The company’s proactive adjustment in its product portfolio is vital amid expectations of declining COVID-related revenues, with management raising its full-year guidance midpoint slightly. This …

Vinay Lochav | 25 August 2026

Tempest Therapeutics (NASDAQ: TPST) Appoints Nicholas Rossettos as CFO Following Resignation

Tempest Therapeutics, Inc. (NASDAQ: TPST) will see a significant change in its financial leadership with the appointment of Nicholas Rossettos as Chief Financial Officer. Rossettos is set to take over the role effective September 1, 2026, following the resignation of Justin Trojanowski, who has …

Vinay Lochav | 25 August 2026

Layoffs Drive Demand for COBRA Coverage Amid Rising Costs

In the wake of rising layoffs, many individuals are turning to COBRA forHealth Insurancecoverage, with reports showing a notable increase in inquiries. Job losses often lead employees to seek this temporary insurance option, which allows them to continue their previous employer's health plan. The …

Vinay Lochav | 25 August 2026

Cancer Vaccine Breakthrough Boosts Biotechs, BNTX Shares Surge 21%

Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) celebrated a significant milestone on August 19, 2026, by announcing favorable topline results from their Phase 3 clinical trial for intismeran autogene. This innovative individualized neoantigen therapy outperformed Keytruda alone in terms of recurrence-free survival rates for …

Vinay Lochav | 25 August 2026

Novo Nordisk Teams Up With AWS for AI-Driven Drug Research

Novo Nordisk has entered a significant partnership with Amazon Web Services (AWS) to enhance its drug discovery capabilities through the integration of advanced artificial intelligence and cloud computing. The initiative establishes AWS as the company’s primary cloud service provider, expanding its collaboration beyond administrative …

Vinay Lochav | 25 August 2026

Oruka Therapeutics (NASDAQ: ORKA) Appoints Todd Edwards CCO With $525K Salary

Oruka Therapeutics, Inc. (NASDAQ: ORKA) has appointed Todd Edwards to the position of Chief Commercial Officer, commencing his tenure on August 24, 2026. Edwards, who is 63 years old, will earn an annual base salary of $525,000. He steps into a vital role aimed …

Vinay Lochav | 25 August 2026

Johnson & Johnson Proposes $5.5 Billion Talc Settlement, Investor Concerns Rise

Settlement Could Resolve Long-Standing Legal Issues

Vinay Lochav | 25 August 2026

Jupiter Neurosciences Raises $2M Through Direct Offering (NASDAQ: JUNS)

This transaction closed on August 24, 2026, and provides essential capital for the company. The funds raised significantly enhance its financial position and stockholders' equity, which is now confirmed to be above $2.5 million, effectively helping it to maintain compliance with Nasdaq's listing requirements. …

Vinay Lochav | 25 August 2026
Support

Hi! How can we help you today?

Loading…